Celldex Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$1.33 | -$0.37 | -$0.69 |
| Q2 2024 | 2 | -$1.13 | -$0.32 | -$0.59 |
| Q3 2024 | 2 | -$1.29 | -$0.36 | -$0.67 |
| Q4 2024 | 7 | -$0.86 | -$0.64 | -$0.73 |
| Q1 2025 | 3 | -$0.94 | -$0.69 | -$0.82 |
| Q2 2025 | 2 | -$1.63 | -$0.46 | -$0.85 |
| Q3 2025 | 2 | -$1.62 | -$0.45 | -$0.84 |
| Q4 2025 | 2 | -$1.68 | -$0.47 | -$0.88 |
Celldex Therapeutics, Inc. Earnings Date And Information
Celldex Therapeutics, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.64 earnings per share for the quarter, topping analysts' consensus estimates of $-0.69 by $0.05. The company had revenue of 3.19 M for the quarter and had revenue of 6.88 M for the year. Celldex Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.92 diluted earnings per share) and currently has a price-to-earnings ratio of -11.63. Celldex Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based on prior year's report dates.
Celldex Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.69 | -$0.64 | 0.05 | $835,556 | $3.19 M |
| 08/08/2024 | Q2 2024 | -$0.59 | -$0.54 | 0.05 | $854,286 | $2.50 M |
| 05/06/2024 | Q1 2024 | -$0.67 | -$0.56 | 0.11 | $156,000 | |
| 02/26/2024 | Q4 2023 | -$0.76 | -$0.83 | -0.07 | $4.13 M | |
| 11/02/2023 | Q3 2023 | -$0.67 | -$0.81 | -0.14 | $583,333 | $1.52 M |
| 08/08/2023 | Q2 2023 | -$0.65 | -$0.65 | 0 | $528,000 | $268,000 |
| 05/04/2023 | Q1 2023 | -$0.63 | -$0.47 | 0.16 | $967,000 | |
| 02/28/2023 | Q4 2022 | -$0.59 | -$0.50 | 0.09 | $1.61 M | |
| 11/09/2022 | Q3 2022 | -$0.57 | -$0.57 | 0 | $360,000 | $407,000 |
| 08/08/2022 | Q2 2022 | -$0.43 | -$1.12 | -0.69 | $400,000 | $163,000 |
| 05/05/2022 | Q1 2022 | -$0.46 | -$0.46 | 0 | $174,000 | |
| 02/28/2022 | Q4 2021 | -$0.42 | -$0.43 | -0.01 | $333,000 | |
| 11/09/2021 | Q3 2021 | -$0.35 | -$0.45 | -0.1 | $1.22 M | $153,000 |
| 08/05/2021 | Q2 2021 | -$0.40 | -$0.34 | 0.06 | $643,333 | $3.48 M |
| 05/06/2021 | Q1 2021 | -$0.32 | -$0.42 | -0.1 | $685,000 | |
| 03/29/2021 | Q4 2020 | -$0.55 | $3.79 M | |||
| 11/05/2020 | Q3 2020 | -$0.34 | -$0.36 | -0.02 | $395,000 | $668,000 |
| 08/06/2020 | Q2 2020 | -$0.77 | -$0.50 | 0.27 | $800,000 | $236,000 |
| 05/06/2020 | Q1 2020 | -$0.70 | -$0.73 | -0.03 | $2.73 M | |
| 03/26/2020 | Q4 2019 | -$0.64 | $887,000 |
Celldex Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Celldex Therapeutics, Inc.'s earnings date?
Celldex Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 24th, 2025 based off last year's report dates.
-
Did Celldex Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Celldex Therapeutics, Inc. (:CLDX) reported $-0.64 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.69 by $0.05.
-
How can I listen to Celldex Therapeutics, Inc.'s earnings conference call?
The conference call for Celldex Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Celldex Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Celldex Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Celldex Therapeutics, Inc. generate each year?
Celldex Therapeutics, Inc. (:CLDX) has a recorded annual revenue of $6.88 M.
-
How much profit does Celldex Therapeutics, Inc. generate each year?
Celldex Therapeutics, Inc. (:CLDX) has a recorded net income of $6.88 M. Celldex Therapeutics, Inc. has generated $-2.92 earnings per share over the last four quarters.
-
What is Celldex Therapeutics, Inc.'s price-to-earnings ratio?
Celldex Therapeutics, Inc. (:CLDX) has a price-to-earnings ratio of -11.63 and price/earnings-to-growth ratio is -1.87.
